AACR 2026 年会
2026 年 4 月 17–22 日 · San Diego · 共 2429 条
#BREASTCANCER
9 人 · 10 条
本事件热度走势
当前热度 1·可比范围峰值 1（4月23日 00:00）·近 24 小时可比范围变化 –·当前参与者 2
参与者计数2
热度走势
zanidatamab 同时绑 HER2 的两个结构域（曲妥珠和帕妥珠各绑一个），不靠化疗的细胞毒。T-DXd 是另一极：用 ADC 的载荷把一线标准往上推，代价是间质性肺病。
三阴性这边，sacituzumab 耐药被写成「蛋白降解通路 + 抑制性微环境」，所以换一个 TROP2 ADC 可能只解决一半。MRD（NSABP-B-59）则给术后加减法提供了分子尺子。
记录
| 药 / 试验 | 读数 | 场景 |
|---|---|---|
| T-DXd + pertuzumabtrastuzumabHER2#BREASTCANCER | PFS HR 0.56；ILD 约 12%，含 2 例 5 级 | DESTINY-Breast09 · 1L HER2+ |
| pumitamig#BREASTCANCER | TNBC cORR 61.5% | PD-L1×VEGF · 与双抗方向交叉 |
| NSABP-B-59#BREASTCANCER#LIQUIDBIOPSY | ctDNA 预测非 pCR 与远处复发 | TNBC 新辅助后 |
其他对照
- zanidatamab无化疗新辅助 pCR 30%
现场
Aya Mohamed | MSc, MD 🎗@Dr_Oncologista Rebecca Shatsky, MD@Dr_RShatsky 总是很有趣，看到人们走到麦克风前提出那些疯狂、非常宽泛且不一定切题的问题。😳 作为主持人要应对这些 #ESMO26 真的很难 我并不反对刚才说的……但是。 #Breastcancer
OncoAlert@OncoAlert Matteo Lambertini, MD PhD@matteolambe Elisa Agostinetto@ElisaAgostinett Aya Mohamed | MSc, MD 🎗@Dr_Oncologista Gil Morgan, MD@weoncologists 引用@OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Retrospective Exploratory Biomarker Analyses From evERA Breast Cancer: A Phase III Trial of Giredestrant + Everolimus in Patients With Oestrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer in the Post-CDK4/6 Inhibitor Setting 🎙️ Sara Tolaney @stolaney1 🔬 Exploratory biomarker analysis of phase III evERA (365 ctDNA-evaluable): giredestrant + everolimus vs SOC endocrine therapy + everolimus in post-CDK4/6i ER+, HER2– aBC. ➡️ PFS HR 0.52 (0.39–0.70) with cTF ≥1%; 0.61 (0.40–0.94) with cTF <1% ➡️ ESR1m: PFS HR 0.58 (D538) and 0.35 (Y537) ➡️ TP53m PFS HR 0.65 (0.45–0.93); PIK3CAm 0.55 (0.36–0.83) ✅ Giredestrant + everolimus maintained greater PFS benefit regardless of cTF status, with benefit across all ESR1 variants and poor prognostic subgroups. #BreastCancer (4Sight Made from Abstracts publicly available at the ESMO website) Pinging OncoAlert Breast Cancer Faculty @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc @Lucarecco @Dr_Oncologista @guiandri76
Mirrors of Medicine@mirrorsmed 引用@OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Final Analysis of the GIM3 FATA Trial: Treatment Schedule and Three Aromatase Inhibitors in Postmenopausal HR+ Early Breast Cancer @PietroDePlacido @antoniorusso_pa @delmastro_lucia @MicheleDelauren @fperrone62 🔬 Randomized trial (n=3697): 5 years of anastrozole, exemestane or letrozole, upfront or after 2 years of tamoxifen. Co-primary: DFS by schedule and by AI. ➡️ Upfront vs switch: DFS HR 0.95 (0.82–1.09); OS HR 0.88 (0.74–1.06) ➡️ 10-year DFS 79.1% anastrozole, 76.6% letrozole, 74.2% exemestane (global p=0.028) ➡️ Exemestane vs anastrozole: adjusted DFS HR 1.23 (1.04–1.46). 10-year OS across AIs: no statistically significant difference (p=0.25) ✅ No schedule superior; exemestane associated with worse DFS. Choice should be individualized by tolerability, comorbidities and cost. #BreastCancer 🎙️ Pietro De Placido 👥 Laura Arenare · Erica Pietroluongo · Giancarlo Bisagni · Maria Sarobba · Antonio Russo · Ferdinando Riccardi · Lucia Del Mastro · Antonio Pazzola · Francesco Cognetti · Jennifer Foglietta · Stefania Gori · Francesco Nuzzo · Adriano Gravina · Michelino De Laurentiis · Roberto Bianco · Grazia Arpino · Sabino De Placido · Ciro Gallo · Francesco Perrone (4Sight Made from Abstracts publicly available at the ESMO website) Pinging OncoAlert Breast Cancer Faculty @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc @Lucarecco @Dr_Oncologista
AACR 2026 现场信号@ Elisa Agostinetto@ElisaAgostinett Sherene Loi, MD@LoiSher 🎉唯一能真正提高早期 HR+ #BreastCancer 一部分患者 pCR 的药物是 #ICB #ESMO2026 #ESMOAmbassadors
Rebecca Shatsky, MD@Dr_RShatsky Yale Cancer Center@YaleCancer Dana-Farber News@DanaFarberNews Oriol Mirallas MD@DrMirallas AACR 2026 现场信号@ Dana-Farber’s Breast Oncology Center@DFCI_BreastOnc UChicagoCancerCenter@UCCancerCenter Dana-Farber’s Breast Oncology Center@DFCI_BreastOnc Pfizer Oncology Medical@PfizerOncMed Pfizer Oncology Medical@PfizerOncMed Fred Hutch Cancer Center@fredhutch Fred Hutch 的 Chris Li（医学博士、哲学博士）在 #AACR26 上介绍了用于 #breastcancer 早期检测的生物标志物 https:// bit.ly/4epxwfU
AACR 2026 现场信号@ Daniel Ghinn@creationdaniel Dana-Farber’s Breast Oncology Center@DFCI_BreastOnc VJ Oncology@VJOncology Fulya Koksalar Alkan@fulya_alkan_ Yale Cancer Center@YaleCancer